Drug intelligence / Profile preview

Dipana

Development stage: Unknown
Lead developer: Sentiss Pharmaceuticals
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Dipana is an oral multi-herb botanical drug product developed by Sentiss Pharma for liver and gallbladder health. It is formulated as a film-coated tablet containing dried aqueous extracts of ten plants, including *Picrorhiza kurroa*, *Andrographis paniculata*, *Eclipta alba*, *Phyllanthus niruri*, *Solanum nigrum*, *Tinospora cordifolia*, *Bacopa monnieri*, *Boerhaavia diffusa*, *Zingiber officinale*, and *Piper longum*. Dipana exhibits hepatoprotective, choleretic, and spasmolytic properties, and has been evaluated in a Phase 4 clinical trial for the treatment of hypomotor-type functional gallbladder disorder (gallbladder dyskinesia).

Brand names: Dipana
Other names: Dipana Tablets

Beyond the preview

Go deeper on Dipana.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dipana.